Become a Member | Print Page | Contact Us | Report Abuse | Sign In
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

News
Wednesday, June 3, 2020   (0 Comments - view/add)
The Call for Nominations has been extended until, Sunday, June 14, 2020, at midnight. »
The Call for Nominations has been extended until, Sunday, June  14, 2020, at midnight.   ITOG  is...
Wednesday, June 3, 2020   (0 Comments - view/add)
The Call for Nominations has been extended until, Sunday, June 14, 2020, at midnight. »
The Call for Nominations has been extended until, Sunday, June  14, 2020, at midnight.   ITOG  is...
Thursday, May 21, 2020   (0 Comments - view/add)
ITOG Nominations are now Open »
  Nominations now open for ITOG Board of Directors Call for nominations will open on  Friday, May 15, 2...
Wednesday, May 20, 2020   (1 Comment - view/add)
ITOG Quarterly Newsletter June 2020 »
ITOG Quarterly Newsletter June 2020  j...
Friday, May 15, 2020   (0 Comments - view/add)
ACCRU-ITOG-1504 Achieves Accrual Goal »
  Congratulations  to  Principal Investigator:  Bryan Haugen  at  The  Univers...
Tuesday, May 12, 2020   (0 Comments - view/add)
FDA Approval for Retevmo (selpercatinib) »
Based on the clinical trial results from the LIBRETTO-001 ( NCT03157128 ) Phase 1/2 trial in RET -altered thyroid cance...
Monday, April 6, 2020   (0 Comments - view/add)
Credit Cards Now Accepted Online »
Credit Cards Now  Accepted Online for Membership Dues Payment We are proud to announce that ITOG website now...
Monday, April 6, 2020   (0 Comments - view/add)
ITOG Robert F. Gagel Discovery Award Recipient Carmelo Nucera, MD »
Please join us in congratulating  the 2019 Robert F. Gagel ITOG Discovery Award  Recipient,  Carmelo Nucera...
Monday, April 6, 2020   (0 Comments - view/add)
LOXO-292 demonstrates promising anti-tumor activity in RET-altered thyroid cancer »
ITOG member Dr. Lori Wirth recently presented progress on a Phase 1/2 study of LOXO-292 at the European Society for Medica...
Monday, April 6, 2020   (0 Comments - view/add)
ITOG Selumetinib Trial Achieves Accrual Goal! »
ITOG Selumetinib Trial Achieves Accrual Goal! Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloa...
Tuesday, March 10, 2020   (0 Comments - view/add)
Selpercatinib (LOXO-292) demonstrates promising anti-tumor activity in RET-altered thyroid cancers »
ITOG member Dr. Lori Wirth, Massachusetts Gen eral Hospital and Harvard Medical School, Boston, MA, recently presented pro...
Friday, October 11, 2019   (0 Comments - view/add)
ITOG Board of Directors Announces a New International Board Member »
ITOG is pleased to announce that Dr. Sophie Leboulleux has been elected as the newest international member of the ITOG Boa...

Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495

614-293-9779

 

Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.